ClinicalTrials.gg
CompletedNCT00272740Updated Feb 9, 2007

SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

A Phase 2 interventional study of Fulvestrant in Breast Neoplasms, sponsored by AstraZeneca. Completed at 8 sites in 2 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2007-02-09.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
44th of 94
93 · median 71
Started
2000
with 1 other
Phase 2
59 of 95
8 open now
Registered
18th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 44th largest by enrollment of the 94 interventional ones that give a count, is one of 2 that started in 2000, is one of 59 in phase 2, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • breast cancer
  • fulvestrant
  • Faslodex
  • hormonotherapy
  • aromatase inhibitor failure
  • Advanced breast cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological/cytological confirmation of breast cancer
  • progression under treatment with an aromatase inhibitor
  • At least one measurable or non-

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for breast cancer with more than 2 different hormonal agents
  • More than 1 chemotherapy for advanced disease
  • Presence of life-threatening visceral disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate

Secondary outcomes

  1. Duration of clinical benefit

  2. Time to progression

  3. Duration of response

  4. Time to treatment failure

  5. Safety and tolerability

  6. 6. clinical benefit rate according to HER2/neu status

07

Study locations

8 sites
  • Research Site
    Leuven, Belgium
  • Research Site
    Aarau, Switzerland
  • Research Site
    Bern, Switzerland
  • Research Site
    Genf, Switzerland
  • Research Site
    Lausanne, Switzerland
  • Research Site
    Mendrisio, Switzerland
  • Research Site
    Milano, Switzerland
  • Research Site
    St.Gallen, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00272740
Lead sponsor
AstraZeneca
First posted
Jan 9, 2006
Start date
Mar 2000
Last update
Feb 9, 2007

Study contacts

AstraZeneca Switzerland Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion